ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,903.40
-0.23%
Dow Jones
43,498.58
0.21%
US Dollar vs MXN
20.34881
0.33%
Brent Oil
73.525
0.94%
Bitcoin
96,742.82
2.53%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Noticias

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:HCM
FechaHoraFuenteTítuloSímboloCompañía
20/11/202403:30RNS Regulatory NewsHutchmed (China) Limited Appointment of Independent Non-executive DirectorLSE:HCMHutchmed (china) Limited
06/11/202401:00RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at ASH and ESMO AsiaLSE:HCMHutchmed (china) Limited
31/10/202407:02Alliance NewsAlliance NewsHutchmed China receives first milestone payment for Takeda drug salesLSE:HCMHutchmed (china) Limited
31/10/202403:30RNS Non-RegulatoryHutchmed (China) Limited First Commercial Milestone PaymentLSE:HCMHutchmed (china) Limited
31/10/202403:30RNS Regulatory NewsHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
21/10/202403:30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
16/10/202403:52Alliance NewsAlliance NewsTOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising resultsLSE:HCMHutchmed (china) Limited
16/10/202401:00RNS Regulatory NewsHutchmed (China) Limited SAVANNAH: clinically meaningful response rateLSE:HCMHutchmed (china) Limited
24/09/202402:49Alliance NewsAlliance NewsTakeda Pharmaceutical says Fruzaqla cancer drug gets Japan backingLSE:HCMHutchmed (china) Limited
24/09/202402:00RNS Regulatory NewsHutchmed (China) Limited Japan Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
09/09/202401:00RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at ESMO and WCLCLSE:HCMHutchmed (china) Limited
30/08/202406:24Alliance NewsAlliance NewsHutchmed "disappointed" as it withdraws fruquintinib applicationLSE:HCMHutchmed (china) Limited
30/08/202401:00RNS Regulatory NewsHutchmed (China) Limited Update on Fruquintinib for Gastric Cancer in ChinaLSE:HCMHutchmed (china) Limited
22/08/202403:30RNS Regulatory NewsHutchmed (China) Limited Standard form for notification of major holdingsLSE:HCMHutchmed (china) Limited
21/08/202403:30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED to Host Expert Call to discuss ITPLSE:HCMHutchmed (china) Limited
06/08/202404:00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
31/07/202408:41Alliance NewsAlliance NewsHutchmed confident of full year guidance for oncology and immunologyLSE:HCMHutchmed (china) Limited
31/07/202406:00RNS Regulatory NewsHutchmed (China) Limited 2024 Interim Results and Business UpdatesLSE:HCMHutchmed (china) Limited
05/07/202413:08Alliance NewsAlliance NewsIN BRIEF: Hutchmed's tazemetostat given priority review in ChinaLSE:HCMHutchmed (china) Limited
04/07/202401:00RNS Non-RegulatoryHutchmed (China) Limited NDA Acceptance in China for TazemetostatLSE:HCMHutchmed (china) Limited
28/06/202406:35RNS Non-RegulatoryHutchmed (China) Limited Overseas Regulatory Announcement: Form F-3 FilingLSE:HCMHutchmed (china) Limited
28/06/202403:30RNS Regulatory NewsHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
26/06/202403:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2024 HY Financial ResultsLSE:HCMHutchmed (china) Limited
24/06/202404:30RNS Non-RegulatoryHutchmed (China) Limited Save the Date: HUTCHMED to Present R&D UpdatesLSE:HCMHutchmed (china) Limited
24/06/202404:00Alliance NewsAlliance NewsIN BRIEF: Hutchmed China notes Takeda obtains EU approval for FruzaqlaLSE:HCMHutchmed (china) Limited
24/06/202401:00RNS Regulatory NewsHutchmed (China) Limited European Commission Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
17/06/202404:32Alliance NewsAlliance NewsHutchmed celebrates "promising" results for sovleplenib in ChinaLSE:HCMHutchmed (china) Limited
17/06/202401:00RNS Non-RegulatoryHutchmed (China) Limited Lancet Publish Phase III ESLIM-01 ResultsLSE:HCMHutchmed (china) Limited
07/06/202412:13Alliance NewsAlliance NewsIN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506LSE:HCMHutchmed (china) Limited
07/06/202401:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase I Trial of HMPL-506LSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Su Consulta Reciente

AQSE
CPP.GB
CPP
BIT
1A
Agilent Technologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados